Key Points
Riskiest biotech stocks are drawing fresh attention as investors chase the kind of upside that rarely shows up in more mature companies. But the tradeoff is brutal: for clinical-stage biotech, valuation can hinge on a small number of trials, future regulatory outcomes, and whether cash lasts long enough to reach key data.
Two names now stand out in this high-stakes corner of the market: Opus Genetics and EyePoint Pharmaceuticals. Both have surged this year, both are still in clinical-stage development, and both have analyst price targets implying triple-digit upside—over 300% in the most bullish cases.
This is not a low-drama bet. These riskiest biotech stocks are exactly the type that can reward investors if clinical milestones land as hoped, or punish them if timelines slip, trial results disappoint, or funding needs increase.
Why the riskiest biotech stocks can swing so sharply
Riskiest biotech stocks often come with the same core profile: major promise, major uncertainty.
These companies are pushing risk to the extreme because key clinical data is still ahead, cash burn can be heavy, and much of the valuation depends on whether trials deliver. When optimism builds, expectations can move quickly. When concerns rise, the downside can be just as sudden.
Opus Genetics and EyePoint Pharmaceuticals fit that template. Each company is valued at about $1.4 billion. Each has a lead clinical effort where execution matters. And each has Wall Street analysts projecting substantial upside—if the clinical story holds.
Riskiest biotech stocks pick No. 1: Opus Genetics
Riskiest biotech stocks don’t get much bolder than Opus Genetics (IRD), a clinical-stage biopharmaceutical company developing gene therapies aimed at restoring vision and preventing blindness in people with inherited retinal diseases.
Opus Genetics is valued at $1.4 billion. The stock is up 60.3% year-to-date, and Wall Street expectations remain aggressive.
Still, the upside case rests on the same pillars that create the risk: clinical success, regulatory outcomes, and ongoing funding.
What Opus Genetics is building
Opus Genetics is developing one-time, long-lasting medicines designed to address the underlying genetic causes of serious eye disorders rather than treating symptoms.
A key program is OPGx-LCA5, a gene therapy targeting Leber Congenital Amaurosis (LCA5). The company has shared early clinical data from a Phase 1/2 trial.
Those early results included:
- Significant increases in cone-mediated vision in pediatric participants over three months
- Durability of response in adult participants out to 18 months
The early findings are described as intriguing, but they come with a crucial limitation: they are based on a limited number of individuals. That makes long-term efficacy and broader application uncertain—one of the main reasons Opus sits firmly among the riskiest biotech stocks investors are watching.
Regulatory engagement raises both hope and pressure
Opus Genetics recently completed a successful FDA Regenerative Medicine Advanced Therapy (RMAT) meeting for OPGx-LCA5. That opens the door to a potentially accelerated regulatory pathway.
It is a positive development, but it also raises expectations. In clinical-stage biotech, accelerated pathways can sharpen the market’s focus on timelines, trial execution, and the ability to translate early signals into broader, durable outcomes.
Funding runway and dilution risk remain central
Opus Genetics reported a net loss of $17.5 million in the third quarter.
The company ended the quarter with $30.8 million in cash and later raised about $23 million through an equity offering. That brought total liquidity to over $50 million.
Management intends to use that cash to fund operations into the second half of 2027. For investors, that timeline matters because it suggests the company expects to reach important clinical milestones before another funding round is required. If delays hit, dilution risk could rise or strategic plans may have to change.
That funding uncertainty—paired with clinical dependency—is why Opus Genetics remains one of the riskiest biotech stocks with potentially outsized payoff.
What analysts are projecting for Opus stock
Wall Street rates Opus stock a “Strong Buy.”
Among nine analysts covering the stock:
- Eight rate it “Strong Buy”
- One rates it “Hold”
The average analyst target price is $7.78, implying a 285% increase over current levels. Analysts have set a high price target of $9, implying the stock could rise as much as 345% over the next year.
Those targets highlight the appeal of riskiest biotech stocks: they can offer staggering upside projections, but only if the clinical and regulatory path holds together.
Riskiest biotech stocks pick No. 2: EyePoint Pharmaceuticals
Riskiest biotech stocks also include EyePoint Pharmaceuticals (EYPT), another clinical-stage biopharmaceutical company focused on developing long-lasting treatments for serious retinal diseases.
EyePoint is valued at $1.4 billion and has delivered an even bigger move this year, up 107.5% year-to-date.
The risk is concentrated. Expectations are heavily tied to a single lead program, DURAVYU.
What DURAVYU is and why it matters
DURAVYU is an experimental sustained-release therapy being developed for:
- Wet age-related macular degeneration (wet AMD)
- Diabetic macular edema (DME)
The program is currently in Phase 3 development, placing EyePoint at a crucial point where clinical execution and upcoming trial data can heavily influence the company’s worth.
For wet AMD, EyePoint’s Phase 3 LUGANO and LUCIA trials have reached full enrollment.
The company expects:
- Top-line data from LUGANO in mid-2026
- LUCIA data to follow
EyePoint has also launched a pivotal Phase 3 program in DME, including two similar non-inferiority trials named COMO and CAPRI.
In a market that can reprice clinical-stage companies rapidly, these Phase 3 timelines are why EyePoint ranks among the riskiest biotech stocks: so much can ride on a small number of outcomes and a defined data calendar.
Losses reflect the cost of late-stage trials
EyePoint reported a net loss of $59.7 million in the third quarter, driven primarily by rising Phase 3 clinical trial costs.
The company also closed an oversubscribed $172.5 million stock offering, extending its liquidity runway into Q4 2027.
That improved liquidity can reduce near-term funding pressure. But the core dependency remains: positive late-stage data is critical in determining whether more capital will be required later.
With a single lead asset in late-stage development, ambitious plans across two major retinal indications, and a long wait for pivotal data, EyePoint remains firmly in the category of riskiest biotech stocks with high reward potential.
What analysts are projecting for EyePoint stock
Wall Street rates EyePoint stock a “Strong Buy.”
Among 13 analysts covering the stock:
- 11 rate it “Strong Buy”
- One rates it a “Moderate Buy”
- One rates it “Hold”
The average analyst target price is $34.18, implying a 105.1% increase over current levels. The high price target is $68, implying the stock could rise as much as 308% over the next year.
Those numbers put EyePoint in rare territory, and they explain why riskiest biotech stocks like this can attract attention even after strong year-to-date gains.
What investors are really betting on with these riskiest biotech stocks
Riskiest biotech stocks can look like simple “upside stories,” but the underlying bet is more specific.
With Opus Genetics, investors are leaning on:
- Early Phase 1/2 signals for OPGx-LCA5
- The possibility of an accelerated pathway after an FDA RMAT meeting
- The company’s cash and stated runway into the second half of 2027
With EyePoint, investors are leaning on:
- DURAVYU’s Phase 3 execution
- Clear timing markers: LUGANO top-line data due mid-2026, with LUCIA to follow
- Liquidity extended into Q4 2027 after a $172.5 million stock offering
In both cases, the “over 300%” upside projections come from analysts’ targets, and the risk comes from how much has to go right to justify those targets.
Conclusion
Riskiest biotech stocks are delivering a familiar promise to investors: extraordinary upside potential, paired with extraordinary uncertainty.
Opus Genetics is advancing gene therapy work in inherited retinal diseases, supported by early Phase 1/2 observations for OPGx-LCA5 and a completed FDA RMAT meeting, while working with liquidity expected to fund operations into the second half of 2027. Analysts see an average target implying 285% upside, with a high target implying up to 345%.
EyePoint Pharmaceuticals is leaning heavily on DURAVYU, an experimental sustained-release therapy in Phase 3 for wet AMD and DME, with LUGANO top-line data due in mid-2026 and LUCIA to follow, and a liquidity runway extended into Q4 2027. Analysts see a high target implying up to 308% upside.
For investors considering riskiest biotech stocks, the key takeaway is simple: the upside is real on paper, but it depends on clinical execution, timelines, and funding staying on track.
